Pre-operative fractionated stereotactic radiotherapy (FSRT) may produce better outcomes than post-operative FSRT in cancer patients with brain metastases.

Patients with recurrent glioblastoma may derive a greater benefit from sacituzumab govitecan if they have high TROP2 expression.

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

The median overall survival was 10.15 months in patients who received epacadostat and 11.11 months in those who did not. Treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy ...